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The irreversible inhibition of 8-amino-7-oxononanoate syn-
thase by trifluoroalanine involves decarboxylative defluorina-
tion of the inhibitor-PLP aldimine followed by attack of the
conjugated imine by the amino group of the active site lysine
to afford a covalently bound difluorinated intermediatewhich
can subsequently undergo furtherHF losses and hydrolysis to
afford a 2-(pyridoximine phosphate) acetoyl protein adduct.
The a-oxamine synthases are a small but metabolically important
family of pyridoxal phosphate (PLP) dependent enzymes which
typically catalyse the decarboxylative condensation of amino
acids with acyl-CoA derivatives to afford vicinal aminoketones
(Scheme 1).1
Scheme 1 The a-oxamine synthase reactions; AONS (R = CH3, R′ =
(CH2)5CO2H), ALAS (R = H, R′ = (CH2)2CO2H), STP (R = CH2OH,
R′ = (CH2)7CH=CH(CH2)5CH3).
The family includes 8-amino-7-oxononanoate synthase
(AONS), the ﬁrst committed enzyme of the biotin biosynthetic
pathway;2 5-aminolevulinate synthase (ALAS), the enzyme re-
sponsible for generating the precursor of the porphyrin rings
of hemes in microorganisms and animals;3 serine palmitoyl-
transferase (SPT), which catalyses the ﬁrst step in sphingolipid
biosynthesis;4 and 2-amino-3-ketobutyrate CoA ligase (KBL),
which is involved in the threonine degradation pathway.5 KBL
formally catalyses the reverse reaction and is the only member
of the family the mechanism of which does not involve a
decarboxylation step. Mutations in some of these enzymes have
been implicated in a number of human disease states, for example,
hereditary sideroblastic anemia caused by a single amino acid
substitution in erythroid-speciﬁc ALAS (ALAS2)6 and hereditary
sensory neuropathy type I caused by mutations in the SPT
subunit-1 (SPTLC1).7
The similarity of the reactions involved and the high sequence
homology between the different enzymes of the family strongly
suggests that all thea-oxamine synthases share a common catalytic
mechanism. The crystal structures of bacterial AONS, KBL and
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ALAS have now been determined5,8–10 and it is apparent that
all of these have a similar fold and active site geometry. Our
understanding of the chemical mechanisms culminates from the
results of early radiolabeling studies on Rhodobacter spheroides
ALAS,11 and from kinetic studies on E. coli8,9 and Bacillus
sphericus12 AONS, and murine ALAS.13 Crystallographic studies
of the product aldimines of E. coli AONS and KBL and the
substrate aldimine of Rhodobacter capsulata ALAS have also
been carried out.5,9,10 In a recent communication we described
trapping experiments which provide good evidence for a b-
ketoacid intermediate aldimine (AONS-OA) in theAONSreaction
sequence.14 The overall reaction catalysed by AONS can now be
conjectured to take place by the route summarised in Scheme 2.
Since biotin synthesis is restricted to plants and microorgan-
isms there has been signiﬁcant interest in developing speciﬁc
inhibitors of the enzymes of this pathway as potential biocides.15
Halogenated substrate analogues have been usefully exploited
as inhibitors of PLP dependent enzymes, a therapeutic example
being 2,2-diﬂuoromethylornithine which is a suicide inhibitor of
ornithine decarboxylase.16 In the course of ourmechanistic studies
on AONS we have investigated the suicide inhibition of this
enzyme by the substrate analogue, L-triﬂuoroalanine, and here
we describe the characterisation of the covalent enzyme adducts
formed, which reveal that the mechanism of inhibition involves a
complex sequence of reactions.
It is well established that pyridoxal phosphate (PLP) depen-
dent amino acid racemases, transaminases and decarboxylases
can be inhibited by b-halo- and b-polyhalo-analogues of their
substrate amino acids. Several inhibitory mechanisms have been
described.17–21 For several enzymes monohaloalanines act as
competitive inhibitors, while for others they can lead to enzyme
inactivation. The inhibition of alanine racemases by D- and
L-ﬂuoroalanines was studied in some depth by Walsh and his
coworkers and shown to proceed by two different mechanisms
depending on the number of halogen substituents.17 In all cases
Ca-H abstraction and halide loss occurs from the corresponding
amino acid PLP-imine to afford the unsaturated Schiff ’s bases
4–4b. In the monoﬂuoro case, 4 undergoes transimination with
the active site lysine leading to release of dehydroalanine, which
can inactivate the enzyme by attacking the PLP-lysine imine.17a
Where 3,3-diﬂuoroalanine is the substrate the predicted product,
3-ﬂuorodehydroalanine, is produced but Michael attack of the
monoﬂuorinated unsaturated PLP-imine 4a by the amino group
of the active site lysine may lead to reversible formation of
the corresponding covalent adduct 5.17b 3,3,3-Triﬂuoroalanine is
a suicide inhibitor and in the case of alanine racemases, the
diﬂuorinated unsaturated imine 4b, formed as above, undergoes
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Scheme 2 Catalytic mechanism of the AONS reaction.
Michael attack as before with subsequent ﬂuoride loss to give
a stable monoﬂuororinated unsaturated complex 6. The stability
of this structure is surprising and it has been conjectured that
complex formation results in the racemase active site becoming
impermeable to solvent water.17b In contrast the inhibition of
cystathione b-lyase by DL-triﬂuoroalanine results in formation of
a complex with loss of all three ﬂuorine atoms suggesting that in
this case attack of the complex 6 by water does occur. This leads
to further HF loss and formation of the corresponding amide 7.18
Validation of this mechanism was provided by elucidation of the
crystal structure of the lysine adduct 7 formed when cystathionine
b-lyase is incubated with triﬂuoroalanine.22
In our studies we found that incubation of E. coli AONS with
L-triﬂuoroalanine (50mM in pH7.5 phosphate buffer at 25 ◦C) led
to slow inactivation of the enzyme (t 1
2
∼20min) with no detectable
activity remaining after 2 h. However the PLP internal aldimine
chromophore (kmax 390 & 425 nm) characteristic of the active
holoenyme appeared essentially unchanged and no absorption
characteristic of formation of an external aldimine was observed.
The inhibition could not be reversed by prolonged dialysis with
PLP containing buffers. Electrospray mass spectrometry of the
inhibited enzyme showed a molecular ion at 41 746 ± 3 amu
corresponding to an increase of 56 ± 3 amu over the native PLP-
AONS monomer (41 690 amu). Dialysis of the inactivated protein
against 50 mN hydroxylamine removed the PLP cofactor leaving
a protein derivative with a monomer molecular weight of 61 ± 3
greater than that of the apo-enzyme showing that the PLP moiety
was attached by a labile imine bond. When the initial complex
was treated with NaCNBH3 the reduced complex had a molecular
mass of 41 751 ± 3 and showed no change on treatment with
hydroxylamine conﬁrming the presence of a PLP Schiff ’s base
in the unreduced protein adduct. Although consideration of the
AONS mechanism and the previous work on cystathionine b-
lyase had led us to predict that an aminomalonoyl adduct of the
enzyme might be formed, the mass spectrometry results clearly
show that decarboxylation of the substrate skeleton to give an
adduct with a mass consistent with structure 9 (predicted mass
41 747 amu) had occurred. This is unexpected since, although a
decarboxylation occurs in its catalytic mechanism, AONS itself
has no known decarboxylase activity on amino acids. This begs
the question at what stage this decarboxylation (presumably with
concomitant loss of ﬂuoride) occurs and whether a-H proton
abstraction from the triﬂuoroalanine-PLP imine is the ﬁrst step
in the process. An additional uncertainty was the nature of the
enzyme nucleophilic group involved. In alanine racemases and
cystathionine b-lyase the nucleophile is the active site lysine
which both anchors the PLP and acts as the base for a-H
abstraction. However in the analogous adducts formed between
2,2-diﬂuoromethylornithine and ornithine and diaminopimelate
decarboxylases, cysteine thiol groups act as the nucleophiles in the
Michael addition.16,23
To resolve these uncertainties we attempted to prepare the
enzyme triﬂuoroalanine adduct in a crystalline form. However
we were unable to crystallise the preformed adduct and so single
crystals of holo-AONS were soaked in a solution containing L-
triﬂuoroalanine (10 mM) and PLP (10 mM) in crystallisation














































buffer containing 1.6 M ammonium sulfate (1.6 M) and 1,3-
bis[tris(hydroxymethyl)methylamino]propane (200mM) at pH 8.5
and rapidly frozen in liquid nitrogen. The X-ray diffraction data
(space group P3112; a = b = 58.22 A˚, c = 194.83 A˚, and c =
120◦ with k = 1.488 A˚) were collected to a resolution of 1.99 A˚.
The data were reduced with DENZO/SCALEPACK,24 and the
structure reﬁned with SHELX97 starting from the coordinate set
1bs08.25 The reﬁnement calculation was interleaved with several
rounds of model building with the program O.26 Water molecules
were added using the program SHELXWAT.25 The ﬁnal R-factor
was 17.9% and the coordinates have been deposited in the Protein
Data Bank27 with accession number 2G6W; the RCSB code is
rcsb036763. The electron density map shown in Fig. 1 revealed
that the ‘active site’ lysine (lys236) was modiﬁed.
Fig. 1 Electron density around Lys236 calculated with coefﬁcients
3|F obs| − 2|F calc|, acalc and contoured at 1.6r. The diagram was prepared
with the program O.26
A surprising ﬁnding was that the crystal structure was not
that of the ﬁnal 2-aminoacetoyl adduct 9, which contains no
ﬂuorine, but rather that of the diﬂuorinated adduct 8. This implies
that decarboxylation occurs at an early stage in the sequence of
reactions. Amechanistic rationalisation is shown in Scheme 3. The
initial step is formation of the enzyme bound triﬂuoroalanine-PLP
aldimine. Analogy with the mechanisms previously reported for
a-haloamino acid inhibition and the normal catalytic mechanism
of AONS shown in Scheme 2 would suggest that the ﬁrst step
after aldimine formation would be proton abstraction by the
amino group of lys236 at C-2 which would lead to elimination
of a ﬂuoride anion affording 5b, the double bond of which is
activated (by the conjugated carboxylate and imine groups) for
Michael attack by the lysine amino group. However, this would
require deprotonation of the lysine amino group and that the
structure 5b, which is anchored by the lysine side chain and the
PLP group, can then twist to adopt a suitable conformation to
facilitate decarboxylation.
The alternative is that decarboxylation and loss of ﬂuoride
occurs immediately after aldimine formation (Scheme 3). This
gives rise to a reactive 2,3-unsaturated imino species which is
attacked by the amino group of lys236. In the crystal phase the
reaction terminates at this point. However when the reaction
was carried out in solution this complex was not observed. It
is reasonable to assume that the next step is HF loss to give a
second 2,3-unsaturated imine which is attacked by water to give
the intermediate gem hydroxyﬂuoro which then loses HF to give
the amide 9. The lack of stability of the diﬂuorinated intermediate
8 in solution is not unexpected since it has been shown that the
AONS structure undergoes signiﬁcant changes in geometry in the
course of its normal catalytic cycle.9 This inherent ﬂexibility could
allow the diﬂuorinated intermediate complex to adopt a suitable
conformation for HF elimination and allow attack by a solvent
water molecule.
The reason why decarboxylation of triﬂuoroalanine occurs is
unclear since AONS exhibits no native decarboxylase activity
with L- or D-alanine. Decarboxylation in the normal mechanism
occurs after formation of the ketoacid intermediate (AONS-OA
in Scheme 2). In view of the geometric constraints imposed by
binding of the pimeloyl derived side chain and the PLP moiety,
stabilization of the Dunathan-type intermediate conformation
required for a PLP-decarboxylation transition state does not
appear likely and we have suggested that the electron sink in
decarboxylation may be provided by the protonated ketone.14
However, crystallographic studies suggest that, prior to binding
of the pimeloyl CoA substrate, there may be sufﬁcient conforma-
tional ﬂexibility in the active site to allow the carboxylate of the
amino acid-PLP aldimine to interact with a number of potential
Scheme 3 Formation of AONS adducts with triﬂuoroalanine (R = OPO32−).














































Fig. 2 Comparison of the AONS active site in the apo-enzyme (A), the
holo-enzyme (B), the diﬂuoro-adduct (C) and the product aldimine (D). In
the diﬂuoro adduct (C), the two ﬂuorine atoms, one of which obscures the
NZ of Lys236, are green. The ﬁgure was prepared using MOLSCRIPT.28
carboxylate docking sites (his133, asn47, arg361). This would
allow the Ca–CO2 bond to adopt an orientation perpendicular
to the plane of the extended PLP ring imine system and thus
facilitate decarboxylation. Determination of which of the basic
residues interact with the carboxylate in the transition state will
require detailed kinetic studies with single residue mutants.
This study was funded by the BBSRC (Grants B13955 &
SBD07593).
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